(1) By the November interim meeting each year beginning in 2020, the department shall report to the Health and Human Services Interim Committee on: (a) the number of applications and renewal applications filed for medical cannabis cards; (b) the number of qualifying patients and designated caregivers; (c) the nature of the debilitating medical conditions of the qualifying patients; (d) the age and county of residence of cardholders; (e) the number of medical cannabis cards revoked; (f) the number of practitioners providing recommendations for qualifying patients; (g) the number of license applications and renewal license applications received; (h) the number of licenses the department has issued in each county; (i) the number of licenses the department has revoked; (j) the quantity of medical cannabis shipments that the state central patient portal facilitates; (k) the number of overall purchases of medical cannabis and medical cannabis products from each medical cannabis pharmacy; (l) the expenses incurred and revenues generated from the medical cannabis program; and (m) an analysis of product availability in medical cannabis pharmacies.
(a) the number of applications and renewal applications filed for medical cannabis cards;
(b) the number of qualifying patients and designated caregivers;
(c) the nature of the debilitating medical conditions of the qualifying patients;
(d) the age and county of residence of cardholders;
(e) the number of medical cannabis cards revoked;
(f) the number of practitioners providing recommendations for qualifying patients;
(g) the number of license applications and renewal license applications received;
(h) the number of licenses the department has issued in each county;
(i) the number of licenses the department has revoked;
(j) the quantity of medical cannabis shipments that the state central patient portal facilitates;
(k) the number of overall purchases of medical cannabis and medical cannabis products from each medical cannabis pharmacy;
(l) the expenses incurred and revenues generated from the medical cannabis program; and
(m) an analysis of product availability in medical cannabis pharmacies.
(2) The department may not include personally identifying information in the report described in this section.
Copyright ©2024 LegalFix. All rights reserved. LegalFix is not a law firm, is not licensed to practice law, and does not provide legal advice, services, or representation. The information on this website is an overview of the legal plans you can purchase—or that may be provided by your employer as an employee benefit or by your credit union or other membership group as a membership benefit.
LegalFix provides its members with easy access to affordable legal services through a network of independent law firms. LegalFix, its corporate entity, and its officers, directors, employees, agents, and contractors do not provide legal advice, services, or representation—directly or indirectly.
The articles and information on the site are not legal advice and should not be relied upon—they are for information purposes only. You should become a LegalFix member to get legal services from one of our network law firms.
You should not disclose confidential or potentially incriminating information to LegalFix—you should only communicate such information to your network law firm.
The benefits and legal services described in the LegalFix legal plans are not always available in all states or with all plans. See the legal plan Benefit Overview and the more comprehensive legal plan contract during checkout for coverage details in your state.
Use of this website, the purchase of legal plans, and access to the LegalFix networks of law firms are subject to the LegalFix Terms of Service and Privacy Policy.